Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, open-label, multicenter extension study of intravitreally administered
ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization
(CNV) secondary to AMD who have completed the treatment phase of a Genentech sponsored Phase
I or Phase I/II ranibizumab protocol (FVF1770g, FVF2128g, or FVF2425g).